Results 251 to 260 of about 23,261 (287)
Some of the next articles are maybe not open access.
Nature Communications
Invasive candidiasis affects 1.6 million people annually, with high mortality among immunocompromised and hospitalized patients. Echinocandins are frontline antifungals, but rising resistance limits their efficacy. Here, we show that Candida albicans and
Malitha C. Dickwella Widanage +10 more
semanticscholar +1 more source
Invasive candidiasis affects 1.6 million people annually, with high mortality among immunocompromised and hospitalized patients. Echinocandins are frontline antifungals, but rising resistance limits their efficacy. Here, we show that Candida albicans and
Malitha C. Dickwella Widanage +10 more
semanticscholar +1 more source
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
After the start of the COVID-19 pandemic, a rapid rise in reported numbers and wide geographic spread of Candida auris-related invasive infections has been observed globally. However, the contemporary epidemiology of C. auris fungaemias in Greece remains
Joseph Meletiadis +10 more
semanticscholar +1 more source
After the start of the COVID-19 pandemic, a rapid rise in reported numbers and wide geographic spread of Candida auris-related invasive infections has been observed globally. However, the contemporary epidemiology of C. auris fungaemias in Greece remains
Joseph Meletiadis +10 more
semanticscholar +1 more source
Echinocandins: production and applications
Applied Microbiology and Biotechnology, 2013The first echinocandin-type antimycotic (echinocandin B) was discovered in the 1970s. It was followed by the isolation of more than 20 natural echinocandins. These cyclic lipo-hexapeptides are biosynthesized on non-ribosomal peptide synthase complexes by different ascomycota fungi.
Tamás, Emri +3 more
openaire +2 more sources
Journal of Antimicrobial Chemotherapy
Echinocandin drugs are the current first-line therapy for fungal infections caused by Candida spp. Most patients require once-daily intravenous (IV) administration in a hospital or outpatient setting for treatment, which may negatively impact their ...
David R. Andes +7 more
semanticscholar +1 more source
Echinocandin drugs are the current first-line therapy for fungal infections caused by Candida spp. Most patients require once-daily intravenous (IV) administration in a hospital or outpatient setting for treatment, which may negatively impact their ...
David R. Andes +7 more
semanticscholar +1 more source
Echinocandins in Ocular Therapeutics
Journal of Ocular Pharmacology and Therapeutics, 2017Fungal infections of the eye, especially fungal keratitis and endophthalmitis, are major causes of concern and if left untreated could lead to vision loss. Currently, natamycin (polyene antifungal) is the only commercially available topical agent used for the treatment of ocular fungal infections.
Akash, Patil, Soumyajit, Majumdar
openaire +2 more sources
Preparative Biochemistry & Biotechnology, 2020
Echinocandin B, a kind of antimycotic with cyclic lipo-hexapeptides, was produced by fermentation with Aspergillus nidulans using fructose as main carbon source.
Zhong-Ce Hu +4 more
semanticscholar +1 more source
Echinocandin B, a kind of antimycotic with cyclic lipo-hexapeptides, was produced by fermentation with Aspergillus nidulans using fructose as main carbon source.
Zhong-Ce Hu +4 more
semanticscholar +1 more source
Micafungin - The newest echinocandin
Drugs of Today, 2009Micafungin is one of three currently FDA-approved echinocandins. It has potent in vitro activity against Candida species including non-albicans Candida and azole-resistant Candida species and has also demonstrated clinical efficacy against deep-seated Candida infections. Additional in vitro data and preliminary clinical efficacy studies suggest that it
Zelalem, Temesgen +2 more
openaire +2 more sources
Update on Echinocandin Antifungals
Seminars in Respiratory and Critical Care Medicine, 2008Echinocandins are semisynthetic lipopeptides that competitively inhibit an essential cell wall component of Candida and aspergillus. They are generally inactive against other fungi. Resistance to these agents is infrequent to date. Echinocandins exhibit low oral bioavailability and are available only as parenteral formulations that are dosed once daily.
Carol A, Kauffman, Peggy L, Carver
openaire +2 more sources
The Lancet, 2003
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +3 more sources
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +3 more sources
Tetrahedron Letters, 1992
Abstract Sodium cyanoborohydride in trifluoroacetic acid selectively reduced the C5-orn and C4-htyr carbinols to methylene groups in echinocandin lipopeptides. The selective reduction of either hydroxyl is also described. The first conversion of echinocandin B to echinocandin C was accomplished.
James M. Balkovec, Regina M. Black
openaire +1 more source
Abstract Sodium cyanoborohydride in trifluoroacetic acid selectively reduced the C5-orn and C4-htyr carbinols to methylene groups in echinocandin lipopeptides. The selective reduction of either hydroxyl is also described. The first conversion of echinocandin B to echinocandin C was accomplished.
James M. Balkovec, Regina M. Black
openaire +1 more source